UNSPSC 51121917: Deslanoside

This classification denotes a glycoside and cardiotonic agent with the molecular formula C47H74O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YGY317RK75, chemically known as 3beta-(o-beta-d-glucopyranosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-beta-d-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid but generally known as deslanoside, which bears US NIH Compound Identifier 28620.

UNSPSC 51121917 Deslanoside, a Commodity code, encompasses pharmaceutical procurement for state and local public health and emergency medical services operations. State and local governments buy single-source and multi-source generic medications, over-the-counter products, and specialty pharmaceuticals for fire rescue, emergency medical services, public health agencies, and state Medicaid pharmacy benefit programs. Recent solicitations reflect purchasing of advanced life support medications (vasopressors, inotropes, and antiarrhythmics), generic multi-source pharmaceuticals distributed through authorized drug wholesalers, and direct-to-manufacturer prescription programs designed to improve fulfillment efficiency and cost management outside traditional pharmacy benefit manager channels. Issuing bodies include city fire and rescue departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple state and local jurisdictions. The code shows activity across municipal procurement (emergency medical supply), state-level pharmacy benefit administration, and regional cooperative purchasing vehicles that aggregate demand across state and local participants.

Activity concentrates in Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (labetalol, epinephrine, adenosine, and diltiazem vials) for Tampa Fire Rescue with a response date of April 8, 2026, estimated contract value of $40,000.00, and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, closing March 26, 2026, with contract award effective July 1, 2026; MMCAP awards to multiple vendors and distributes them to three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct contracting relationships outside traditional PBM and GPO channels; the RFI closes April 3, 2026, and is exploratory in nature, intended to inform subsequent formal procurement strategy.